TCT 2018 | NEOPRO: A Registry for Acurate neo and Evolut PRO

The purpose of this registry was to compare short-term clinical events and echocardiographic findings in two self-expanding valves used with transfemoral access, Acurate neo and Evolut PRO.

NEOPRO: registro entre Acurate neo y Evolut PROThe registry included a retrospective follow-up of 1551 patients, among whom 1263 received an Acurate neo valve and 288 received an Evolut Pro valve.

 

The procedural success rates according to VARC-2 criteria were high, 90.5% vs. 91.6% (p = 0.7), and the rates of occurrence of moderate-to-severe paravalvular aortic regurgitation were 7.3% vs. 5.7% (p = 0.5), respectively. There were no instances of coronary occlusion in the whole cohort and the rates of permanent pacemaker implantation were low and similar, around 12%.

 

The rates of bleeding and vascular complications were higher among patients in the Acurate neo arm, but this difference disappeared after adjusting these populations according to their clinical characteristics.

 

Original title: Nonrandomized Comparison of Two Transcatheter Heart Valve in Patients with Severe Aortic Stenosis.

Presenter: Azeem Latib.

 

Descargar (PDF, Unknown)


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

*

Top